Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults †

The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (NTRK) gene fusions. These NTRK gene fusions are oncogenic drivers found in most tumour types at a low freq...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Curr Oncol
Asıl Yazarlar: Bebb, D. Gwyn, Banerji, Shantanu, Blais, Normand, Desmeules, Patrice, Gill, Sharlene, Grin, Andrea, Feilotter, Harriet, Hansen, Aaron R., Hyrcza, Martin, Krzyzanowska, Monika, Melosky, Barbara, Noujaim, Jonathan, Purgina, Bibiana, Ruether, Dean, Simmons, Christine E., Soulieres, Denis, Torlakovic, Emina Emilia, Tsao, Ming-Sound
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2021
Konular:
Guidelines
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7903287/
https://ncbi.nlm.nih.gov/pubmed/33467570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/curroncol28010053
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller